A/Prof. Shane R. Thomas

Dr. A/Prof. Shane R. Thomas

Head, Redox Cell Signalling Group, Mechanisms of Disease & Translational Research, Department of Pathology, School of Medical Sciences, Faculty of Medicine, Wallace Wurth Building, University of New South Wales, Sydney, NSW 2052, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
A/Prof. Shane R. ThomasA/Prof. Shane R. Thomas
A/Prof. Shane R. Thomas
Paul WittingPaul Witting
Paul Witting
GDGrant R. Drummond
Grant R. Drummond
The endothelium is essential for the maintenance of vascular homeostasis. Central to this role is the production of endothelium-derived nitric oxide (EDNO), synthesized by the endothelial isoform of nitric oxide synthase (eNOS). Endothelial dysfunction, manifested as impaired EDNO bioactivity, is an important early event in the development of various vascular diseases, including hypertension, diabetes, and atherosclerosis. The degree of impairment of EDNO bioactivity is a determinant of future vascular complications. Accordingly, growing interest exists in defining the pathologic mechanisms involved. Considerable evidence supports a causal role for the enhanced production of reactive oxygen species (ROS) by vascular cells. ROS directly inactivate EDNO, act as cell-signaling molecules, and promote protein dysfunction, events that contribute to the initiation and progression of endothelial dysfunction. Increasing data indicate that strategies designed to limit vascular ROS production can restore endothelial function in humans with vascular complications. The purpose of this review is to outline the various ways in which ROS can influence endothelial function and dysfunction, describe the redox mechanisms involved, and discuss approaches for preventing endothelial dysfunction that may highlight future therapeutic opportunities in the treatment of cardiovascular disease.

14 July 2015 in Clinical Science
Verified
Journal Article
Closed access
PDF file
AYAmanda W.S. Yeung
Amanda W.S. Yeung
ATAndrew C. Terentis
Andrew C. Terentis
NKNicholas Jonathan Cole King
Nicholas Jonathan Cole King
A/Prof. Shane R. ThomasA/Prof. Shane R. Thomas
A/Prof. Shane R. Thomas
IDO1 (indoleamine 2,3-dioxygenase 1) is a member of a unique class of mammalian haem dioxygenases that catalyse the oxidative catabolism of the least-abundant essential amino acid, L-Trp (L-tryptophan), along the kynurenine pathway. Significant increases in knowledge have been recently gained with respect to understanding the fundamental biochemistry of IDO1 including its catalytic reaction mechanism, the scope of enzyme reactions it catalyses, the biochemical mechanisms controlling IDO1 expression and enzyme activity, and the discovery of enzyme inhibitors. Major advances in understanding the roles of IDO1 in physiology and disease have also been realised. IDO1 is recognised as a prominent immune regulatory enzyme capable of modulating immune cell activation status and phenotype via several molecular mechanisms including enzyme-dependent deprivation of L-Trp and its conversion into the aryl hydrocarbon receptor ligand kynurenine and other bioactive kynurenine pathway metabolites, or non-enzymatic cell signalling actions involving tyrosine phosphorylation of IDO1. Through these different modes of biochemical signalling, IDO1 regulates certain physiological functions (e.g. pregnancy) and modulates the pathogenesis and severity of diverse conditions including chronic inflammation, infectious disease, allergic and autoimmune disorders, transplantation, neuropathology and cancer. In the present review, we detail the current understanding of IDO1’s catalytic actions and the biochemical mechanisms regulating IDO1 expression and activity. We also discuss the biological functions of IDO1 with a focus on the enzyme's immune-modulatory function, its medical implications in diverse pathological settings and its utility as a therapeutic target.

1 August 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
A/Prof. Shane R. ThomasA/Prof. Shane R. Thomas
A/Prof. Shane R. Thomas
ATAndrew C. Terentis
Andrew C. Terentis
HCHong Cai
Hong Cai
OTOsamu Takikawa
Osamu Takikawa
ALAviva Levina
Aviva Levina
RSRoland Stocker
Roland Stocker
The heme protein indoleamine 2,3-dioxygenase (IDO) is induced by the proinflammatory cytokine interferon-γ (IFNγ) and plays an important role in the immune response by catalyzing the oxidative degradation of l-tryptophan (Trp) that contributes to immune suppression and tolerance. Here we examined the mechanism by which nitric oxide (NO) inhibits human IDO activity. Exposure of IFNγ-stimulated human monocyte-derived macrophages (MDM) to NO donors had no material impact on IDO mRNA or protein expression, yet exposure of MDM or transfected COS-7 cells expressing active human IDO to NO donors resulted in reversible inhibition of IDO activity. NO also inhibited the activity of purified recombinant human IDO (rhIDO) in a reversible manner and this correlated with NO binding to the heme of rhIDO. Optical absorption and resonance Raman spectroscopy identified NO-inactivated rhIDO as a ferrous iron (FeII)-NO-Trp adduct. Stopped-flow kinetic studies revealed that NO reacted most rapidly with FeII rhIDO in the presence of Trp. These findings demonstrate that NO inhibits rhIDO activity reversibly by binding to the active site heme to trap the enzyme as an inactive nitrosyl-FeII enzyme adduct with Trp bound and O2 displaced. Reversible inhibition by NO may represent an important mechanism in controlling the immune regulatory actions of IDO.

23 December 2009 in Biochemistry
Verified
Journal Article
Closed access
ATAndrew C. Terentis
Andrew C. Terentis
MFMohammed Freewan
Mohammed Freewan
TPTito S. Sempértegui Plaza
Tito S. Sempértegui Plaza
MRMark J. Raftery
Mark J. Raftery
RSRoland Stocker
Roland Stocker
A/Prof. Shane R. ThomasA/Prof. Shane R. Thomas
A/Prof. Shane R. Thomas

1 May 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SMSophie L. Maiocchi
Sophie L. Maiocchi
JKJacqueline Ku
Jacqueline Ku
TTThuan Thai
Thuan Thai
ECEnoch Chan
Enoch Chan
MRMartin D. Rees
Martin D. Rees
A/Prof. Shane R. ThomasA/Prof. Shane R. Thomas
A/Prof. Shane R. Thomas

1 January 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MFMohammed Freewan
Mohammed Freewan
MRMartin D. Rees
Martin D. Rees
TPTito S. Sempértegui Plaza
Tito S. Sempértegui Plaza
EGElias Glaros
Elias Glaros
YLYean Jin Lim
Yean Jin Lim
A/Prof. Shane R. ThomasA/Prof. Shane R. Thomas
A/Prof. Shane R. Thomas
The heme enzyme indoleamine 2,3-dioxygenase (IDO) is a key regulator of immune responses through catalyzing l-tryptophan (l-Trp) oxidation. Here, we show that hydrogen peroxide (H2O2) activates the peroxidase function of IDO to induce protein oxidation and inhibit dioxygenase activity. Exposure of IDO-expressing cells or recombinant human IDO (rIDO) to H2O2 inhibited dioxygenase activity in a manner abrogated by l-Trp. Dioxygenase inhibition correlated with IDO-catalyzed H2O2 consumption, compound I-mediated formation of protein-centered radicals, altered protein secondary structure, and opening of the distal heme pocket to promote nonproductive substrate binding; these changes were inhibited by l-Trp, the heme ligand cyanide, or free radical scavengers. Protection by l-Trp coincided with its oxidation into oxindolylalanine and kynurenine and the formation of a compound II-type ferryl-oxo heme. Physiological peroxidase substrates, ascorbate or tyrosine, enhanced rIDO-mediated H2O2 consumption and attenuated H2O2-induced protein oxidation and dioxygenase inhibition. In the presence of H2O2, rIDO catalytically consumed nitric oxide (NO) and utilized nitrite to promote 3-nitrotyrosine formation on IDO. The promotion of H2O2 consumption by peroxidase substrates, NO consumption, and IDO nitration was inhibited by l-Trp. This study identifies IDO as a heme peroxidase that, in the absence of substrates, self-inactivates dioxygenase activity via compound I-initiated protein oxidation. l-Trp protects against dioxygenase inactivation by reacting with compound I and retarding compound II reduction to suppress peroxidase turnover. Peroxidase-mediated dioxygenase inactivation, NO consumption, or protein nitration may modulate the biological actions of IDO expressed in inflammatory tissues where the levels of H2O2 and NO are elevated and l-Trp is low.